Form 4: Maze Therapeutics Director Jonathan E. Lim Reports Beneficial Ownership Changes

Sentiment:

SEC Form 4 Filing


Director Jonathan E. Lim reports changes in beneficial ownership of Maze Therapeutics stock following the conversion of preferred stock and option transactions.

Summary

  • Jonathan E. Lim, a director at Maze Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
  • The changes are primarily due to the conversion of Series A and Series B preferred stock into common stock upon the closing of Maze Therapeutics' initial public offering (IPO).
  • The conversion ratios were 1-for-0.1037236801 for Series A and 1-for-0.1211056427 for Series B.
  • Lim also reported transactions involving stock options, including the grant of new options and the cancellation of old options with a repriced exercise price.
  • The reported transactions include both direct and indirect ownership through City Hill, LLC, where Lim is the managing partner.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

  • Shareholders are informed about changes in insider ownership, which can influence investor confidence.

Key Dates

DateDescription
04/01/2023First tranche vesting date for stock option granted on March 9, 2023.
12/09/2024Date of option repricing approved by the Issuer's Board of Directors.
01/24/2025Effective date of 1:9.641 reverse stock split.
01/01/2025First tranche vesting date for stock option granted on December 9, 2024.
02/03/2025Date of transactions involving conversion of preferred stock and stock options.
02/04/2025Date of Form 4 filing.
03/08/2033Expiration date of cancelled stock option.
12/08/2034Expiration date of new stock option.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.